SCHEMBL25977472

SCHEMBL25977472

COC(=O)c1cc(OC)c(OC)c(OS(=O)(=O)C(F)(F)F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.46
TPMT P51580 1/20 0.45
KDM4E B2RXH2 3/20 0.45
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
TSHR P16473 2/20 0.43
USP2 O75604 1/20 0.43
TUBB1 Q9H4B7 2/20 0.43
CYP3A4 P08684 1/20 0.43
PKM P14618 1/20 0.42
MAPT P10636 2/20 0.42
HTT P42858 2/20 0.42
LMNA P02545 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
ALDH1A1 P00352 2/20 0.41
HTR1A P08908 1/20 0.41
HPGD P15428 1/20 0.41
HTR2C P28335 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24857231 0.91 TPMT (0.44) THRBTPMTKDM4EMEN1KMT2A
SCHEMBL25980111 0.90 KDM4E (0.44) THRBTPMTKDM4EMEN1KMT2A
SCHEMBL17893866 0.86 TUBB1 (0.44) THRBTPMTKDM4ETSHRUSP2
SCHEMBL22026532 0.85 TSHR (0.47) THRBTPMTKDM4EMEN1KMT2A
SCHEMBL2470307 0.85 ALDH1A1 (0.48) THRBTPMTKDM4ECYP3A4MAPT
SCHEMBL14150105 0.84 KDM4E (0.41) THRBTPMTKDM4EKMT2ACYP3A4
SCHEMBL730998 0.84 NOTUM (0.44) THRBTPMTKDM4EKMT2ACYP3A4
SCHEMBL2934710 0.83 MAPT (0.57) TPMTKDM4EMEN1KMT2ATSHR
SCHEMBL31336381 0.83 MAPT (0.57) TPMTKDM4EMEN1KMT2ATSHR
SCHEMBL31238876 0.83 MAPT (0.57) TPMTKDM4EMEN1KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS iTeos Belgium SA (BE) 2023-06-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203058-A1 MACROCYCLIC DIAMINE DERIVATIVES AS ENT INHIBITORS FOR THE TREATMENT OF CANCERS, AND COMBINATION THEREOF WITH ADENOSINE RECEPTOR ANTAGONISTS ENTPD1, SLC29A1, ENTPD5 THRB 2281/4885TPMT 1218/4885KDM4E 2852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.